Phesgo Starts (and the Weekly Phase Begins)
A new chapter of treatment begins: Phesgo (HER2-targeted therapy) starts, alongside the move into weekly chemo. Different rhythm, different side effects, same goal — maximum response before surgery.
Phesgo Starts (and the Weekly Phase Begins)
On 30 January 2026, treatment shifted into a new rhythm.
This is when Phesgo starts — the HER2-targeted part of the plan — and the calendar moves into the weekly phase.
What is Phesgo (in plain English)?
Phesgo combines two HER2-targeted drugs:
- Pertuzumab
- Trastuzumab
They’re designed to target HER2-positive cancer cells more specifically than chemotherapy alone. Chemo is the broad attack; HER2 treatment is the targeted one.
Why this feels like a new chapter
EC was intense but spaced out. Weekly appointments are different: less time to “reset”, more of a steady drumbeat. It’s a practical change (more hospital visits), and it’s a mental change too — you’re in it, week after week.
The goal stays the same:
- shrink what’s there
- clear what can’t be seen
- walk into surgery with the best possible odds
Linking this to the detail pages
If you want the “what an appointment involves” explanations:
- EC: see the dedicated EC page
- Weekly Taxol: see the dedicated weekly Taxol page (this phase runs alongside HER2 therapy)